113 results about "Renal glomerulus" patented technology

This invention provides a compound of formula (I):

or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; processes for the synthesis or manufacture of the compound of formula (I), or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof; and the use of said compound, or a crystalline form thereof, or a pharmaceutical composition thereof, or an oral pharmaceutical dosage form thereof, for the treatment of patients suffering from or subject to diseases, disorders or conditions involving cell survival, proliferation, and migration, including cardiovascular disease (e.g., arteriosclerosis and vascular reobstruction), cancer, (e.g., AML and malignant glioma)glomerulosclerosis, fibrotic disease and inflammation.

The invention provides an in-vitro detection method of human cystatin C. The method adopts a magnetic particle separation chemiluminescence immunoassay technology which is a product integrating an enzyme labeling technology, a magnetic particle separation technology and a chemiluminescence detection technology and has the advantages of high sensitivity, good specificity, good repetitiveness, and the like. The method can be used for measuring the content of cystatin C in the serum, the plasma and the urine of a person, and the indexes are mainly used for clinically evaluating the renal function and mainly used for monitoring the filtration rate of glomerulus, the renal tubular dysfunction and various secondary nephropathies.

Disclosed is a Chinese medicament for treating acute glomerular nephritis wherein the recipe includes astragalus root 20g, root of red rooted saliva 15g, cogongrass rhizome 40g, rhizome smilacis glabrae 100g, motherwort 20g, malt 30g, arctium fruit 10g, bletilla tuber 12g, kudzuvine root 8g, cordate houttuynia 10g, plantain seeds, polyporus umbellatus each 20g, alkanna tinctoria, eclipta, notoginseng each 30g, Achyranthes bidentatae 25g, sweet basil, ledebouriella root each 30g. The Chinese medicament has simplified recipe, easy preparing process and low price.

The present invention relates to Chinese medicine for preventing and treating chronic renal lomerulus diseases, and is especially the medicine composition of one kind of compound Chinese medicine Tongmai oral liquid and its preparation process. The medicine composition is compounded with the effective parts of astragalus root, notoginseng, red sage and angelica, and contains compound polysaccharide and compound saponin in the ratio of 1-12. The medicine composition has the functions of benefiting Qi, promoting blood circulation, strengthening immunological stability, lowering the permeability of filtering membrane in renal lomerulus, improving microcirculation, etc., so that it can improve and stabilize kidney function.

The invention discloses application of a Chinese medicinal composition in preparing a medicament for treating chronic glomerulonephritis. The Chinese medicinal composition consists of eight gouts of Chinese medicaments such as astragalus root, steatite, selfheal, and the like. The medicinal composition has the efficacies of promoting qi transformation, promoting diuresis and softening hardness to dissipate stagnation. The clinical research shows that the Chinese medicinal composition can effectively treat the chronic glomerulonephritis.

Uteroglobin has been discovered to prevent IgA mediated diseases, such as IgA nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals, and animals in which uteroglobin-protein expression is reduced by antisense technology, also provide systems for studying IgA mediated diseases, and screening for appropriate treatments.

The present invention provides a use of compounds from Antrodia camphorata in manufacturing medicaments for treating kidney diseases, wherein the compounds is represented by formula (I):

wherein R₁ is a hydrogen atom or acetyl group, R₂ is

wherein the kidney disease is glomerulosclerosis or glomerulonephritis.

The embodiment of the invention relates to the field of immunodiagnosis, in particular to a human alpha1-microglobulin (MG) determination kit with high sensitivity and a wide detection range. The human alpha1-MG determination kit provided by the embodiment of the invention comprises a reagent 1, a reagent 2 and human alpha1-MG calibration products of different gradient concentrations, wherein thereagent 2 comprises carboxylated latex microspheres labeled with a human alpha1-MG monoclonal antibody only and carboxylated latex microspheres labeled with a human alpha1-MG polyclonal antibody only;and the average particle size of the carboxylated latex microspheres labeled with the human alpha 1-MG monoclonal antibody only is larger than that of the carboxylated latex microspheres labeled withthe human alpha 1-MG polyclonal antibody. The human alpha1-MG determination kit provided by the invention can complete the detection of a single sample within 10 minutes with excellent precision, accuracy and anti-interference performance, can well reflect the renal tubular reabsorption function and glomerular filtration function, is very suitable for clinical biochemical analyzers, and greatly facilitates clinical examination.

The present invention relates to the novel use of certain piperidinyl-indole derivatives in the treatment of patients suffering from renal diseases or disorders, and in particular for the treatment ofpatients suffering from C3G (C3 glomerulopathy) and IgAN (IgA nephropathy).

The invention relates to new medical applications of a natural monomer compound pterostilbene, in particular to applications of the pterostilbene in preparation of medicines for preventing and treating a chronic glomerular disease, and applications of pterostilbene in preparation of medicines for preventing and treating progressive chronic glomerular disease. Animal test results show that the pterostilbene has an obvious effect on prevention and improvement of a glomerular function and an organic injury of a fructose model rat renal. The pterostilbene is matched up with relevant adjuvants, a conventional preparation method can be utilized to obtain a health care product or a medicine aiming at preventing and treating the glomerular disease. The above health care product and the medicine can be used for the diseases relevant to the chronic glomerular lesion, such as diabetes and metabolic syndrome and the like, so that the glomerular progressive course in the relevant diseases can be delayed and improved.

The invention discloses a detecting system for a glomerular filtration rate and relates to the technical field of medical treatment and public health. The detecting system comprises a patient information collecting terminal, a serum creatinine detecting terminal and a glomerular filtration rate detecting device, wherein the patient information collecting terminal is used for collecting the basic patient information from a patient database; the serum creatinine detecting terminal is used for detecting the serum creatinine level of a patient; the glomerular filtration rate detecting device is used for detecting the glomerular filtration rate of the patient according to the basic patient information collected by the patient information collecting terminal and the serum creatinine level detected by the serum creatinine detecting terminal. The detecting system provided by the invention can be used for simply and directly supplying an accurate glomerular filtration rate result to a doctor and the patient and the burden of the patient is relieved.

The invention relates to a method for reproducing paraffin sections from kidney biopsy immunofluorescence frozen residual tissues, which comprises the following steps: quickly unfreezing the frozen residual kidney tissues by using a PBS buffer solution, dissolving OCT (Optical Coherence Tomography) gel, reproducing the paraffin sections, carrying out special dyeing by using the paraffin sections,and carrying out light microscope examination to obtain the paraffin sections toooooooo make up the condition that no glomerulus exists or the glomerulus is too little in the light microscope examination. The method has the advantages that the steps are simple, the operation is fast and convenient, the dyeing effect is good, the secondary kidney biopsy of the patient can be effectively avoided, and the pain and the economic burden of the patient are reduced.

The invention relates to a pure traditional Chinese medicine preparation for treating glomerular diseases. The pure traditional Chinese medicine preparation is prepared from the following raw materials in parts by weight: 30 parts of membranous milkvetch root, 12 parts of amur corktree bark, 15 parts of rhubarb, 40 parts of glabrous greenbrier rhizome, 20 parts of radix salviae miltiorrhizae, 15 parts of oriental waterplantain rhizome, 20 parts of epimedium herb, 15 parts of lalang grass rhizome and 30 parts of motherwort herb, and prepared by decoction, filtration, concentration of filtrate and drying. The pure traditional Chinese medicine preparation has significant efficacy for kidney diseases comprising acute and chronic glomerulonephritis, nephrotic syndrome, hypertensive nephropathy, diabetic nephropathy and early renal insufficiency caused by various reasons; furthermore, the raw materials are easily available, the production process is simple, the toxicity and side effects are small, and the administration is convenient, thereby providing the effective pure traditional Chinese medicine preparation for treating the kidney diseases.

Disclosed is a Chinese medicinal formulation for treating chronic glomerular nephritis wherein the recipe includes eucommia bark 15g, nutgrass flatsedge rhizome 15g, psoralea fruit 15g, Achyranthes bidentatae 15g, pig's kidney 2 pieces, notoginseng 30g and astragalus root 20g. The medicament is prepared through conventional processes with easy accessibility of raw materials, simplified formulation and preparing procedures, and low cost of medicament production.

Measuring the number of glomeruli in the entire, intact kidney using non-destructive techniques is of immense importance in studying several renal and systemic diseases. In particular, a recent Magnetic Resonance Imaging (MRI) technique, based on injection of a contrast agent, cationic ferritin, has been effective in identifying glomerular regions in the kidney. In various embodiments, a low-complexity, high accuracy method for obtaining the glomerular count from such kidney MRI images is described. This method employs a patch-based approach for identifying a low-dimensional embedding that enables the separation of glomeruli regions from the rest. By using only a few images marked by the expert for learning the model, the method provides an accurate estimate of the glomerular number for any kidney image obtained with the contrast agent. In addition, the implementation of our method shows that this method is near real-time, and can process about 5 images per second.

The invention combines the polypeptide donkey-skin gelatins with different weight-average molecular weights and then adds tryptophan into the combined polypeptide donkey-skin gelatins to prepare the plasma substitutes containing gelatin molecules with different molecular weights. The process has the advantages that: smaller molecules can easily pass through renal glomerulus, which contributes to diuretics at the early stage of introduction; bigger molecules are left in the blood vessels, and the dilatation effect is prolonged; and the increase of the tryptophan can stimulate the synthesis of albumins so as to replenish the plasma proteins in huge loss.

The invention relates to the technical field of medicine. The clinical manifestations of glomerulonephritis are proteinuria, hematuria, edema, hypertension, etc. Among them, chronic glomerulonephritis has a long course of disease, often has different degrees of renal function damage, and has recurrent attacks, and the prognosis is poor. The purpose of the present invention is to provide the application of Clary sage extract in the preparation of medicine for treating glomerulonephritis. The invention provides an extract of sage ganxie obtained by drying and pulverizing medicinal materials of the roots of sage ganxie, soaking them in water-containing lower alcohol, extracting by percolation or heating, and concentrating and drying the extract. The above-mentioned Clary Sage extract has been confirmed by animal experiments to significantly reduce the urinary protein content of serum sickness glomerulonephritis model rats, and can significantly reduce the swelling of the glomerulus, and also has the ability to reduce blood viscosity and diuresis. therapeutic effect. The invention not only provides a new application for the ganxi sage, but also provides a new treatment drug for the majority of nephritis patients.

The invention provides a traditional Chinese medicinal preparation for treating chronic renal disease and a preparation method thereof. The traditional Chinese medicinal preparation is prepared from the following crude medicines in parts by weight: rheum officinale and safflower on (1-10):(10-1); the crude medicines are prepared into an injection, a freeze-dried powder injection or other oral preparations through certain extraction and purification processes. Animal experiments prove that the traditional Chinese medicinal preparation can be used for significantly improving the hemorheology indexes of mice infected by chronic glomerulonephritis and reducing serum IL-6, IL-8 and TNF-alpha levels; the preparation can be used for remarkably reducing serum urea nitrogen and serum creatinine contents of mice of chronic renal failure and increasing a serum albumin content; moreover, the preparation can be used for improving the various hemorheology indexes and levels of mice of chronic renal failure; a pathological result shows that the traditional Chinese medicinal preparation disclosed by the invention can be used for improving and inhibiting damage of chronic kidney disease and chronic renal failure on kidney; furthermore, the traditional Chinese medicinal preparation prepared by the optimal preparation method disclosed by the invention is more excellent than a traditional Chinese medicinal preparation prepared by a conventional method.

The invention provides a traditional Chinese medicine composition for treatment of chronic renal diseases and chronic renal failure and its preparation method. The traditional Chinese medicine composition is prepared from the raw material medicines of rheum officinale and salvia miltiorrhiza in a weight ratio of 1-10:10-1 by a certain extraction and purification process into an injection, a freeze-dried powder injection or other oral preparations. Animal experiments confirm that, the traditional Chinese medicine composition can obviously improve the hemodynamic indexes of rats subjected to chronic glomerulonephritis, reduces serum IL-6, IL-8, and TNF (tumor necrosis factor)-alpha levels, significantly reduces serum urea nitrogen and serum creatinine contents of rats subjected to the chronic renal failure, increases serum albumin content, and also can improve each hemodynamic index of rats subjected to the chronic renal failure; pathological results show that the traditional Chinese medicine composition can improve and inhibit injures on kidney caused by the chronic renal diseases and chronic renal failure; and the treatment effect of the traditional Chinese medicine preparation prepared by the preparation method provided by the invention is better than that of a traditional Chinese medicine preparation prepared by a conventional method.

The invention aims to solve the problem of cleaning nephritic lesion to clean the renal glomerulus effectively and thoroughly, and restore the functions of the renal glomerulus, clear renal calculus, and cure uremic patients and 290, 000 sufferers from the melamine tainted milk incident. The technical proposal of the invention comprises: cleaning the nephritic lesion by supplying photo-catalytic nanometer active water to the sufferers by drinking, injecting and targeting; and using the oxygenolysis capacity of free radicals in the photo-catalytic nanometer active water to clean the glomerular filtration membrane and the renal tubule effectively and thoroughly, decompose immune complexes or organic complexes deposited thereon, and diminish inflammation simultaneously so as to restore the functions of the renal glomerulus, establish an artificial immune system, and cure the uremia, nephritis, and the like. Simultaneously, the invention is a pioneering invention, the basic theory for the naissance of free radical physics, free radical chemistry and free radical medicine, and a mark for the naissance of new disciplines, and opens up a new era for the development of the human society. The photo-catalytic nanometer active water can be produced by solar energy, has low cost and is easy to widely popularize and apply.

The invention discloses a medicine for treating chronic glomerulonephritis and a nephrotic syndrome and a preparation method thereof. The medicine is mainly prepared from astragalus membranaceus, humifuse euphorbia herb, codonopsis pilosula, dogwood pulp, prepared rehmannia, white atractylodes rhizome, poria cocos and rhizoma alismatis. The prepared medicine has the effects of strengthen the spleen, tonifying the kidney, invigorating Yang, consolidating vital energy, clearing damp and promoting diuresis, and can reduce proteinuria and hematuria to treat the chronic nephritis and the nephrotic syndrome; the medicine is applicable to treatment of proteinuria and hematuria caused by the chronic nephritis and the nephrotic syndrome, and in the traditional Chinese medicine, the syndrome includes spleen deficiency, kidney deficiency, Qi deficiency and damp turbidity.

The invention discloses a cordyceps cicadae polysaccharide, a preparation method and application thereof in preparation of a medicament for preventing renal interstitial fibrosis. The method comprisesthe following steps: pulverizing cordyceps cicadae fruiting bodies, and performing sieving to obtain cordyceps cicadae fruiting body powder; ultrasonically extracting the fruiting body powder with distilled water, and then carrying out ultrahigh pressure treatment; preparing crude polysaccharide of the cordyceps cicadae fruiting body after the treatment; and then performing separation by using DEAE-cellulose anion column chromatography, and performing freeze-drying to obtain the purified polysaccharide. The method successfully prepares the cicada cordyceps polysaccharide treated and modifiedby ultrahigh pressure, and has the advantages of simple steps and higher efficiency. The intervention on a rat glomerular epithelial cell model shows that the polysaccharide can effectively inhibit the proliferation of rat glomerular epithelial cells (HMC), and has wide application prospect in the aspect of preventing renal interstitial fibrosis. The oxidation resistance of the cordyceps cicadae polysaccharide is obviously improved, and the cordyceps cicadae polysaccharide induces the apoptosis of high-glucose rat glomerular mesangial cells, has no toxicity to normal cells, and has good research value and commercial value.

A multicomponent treatment program for kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.